tiprankstipranks
Trending News
More News >
Siegfried Holding AG (CH:SFZN)
:SFZN

Siegfried Holding AG (SFZN) AI Stock Analysis

Compare
2 Followers

Top Page

CH

Siegfried Holding AG

(OTC:SFZN)

Rating:75Outperform
Price Target:
CHF106.00
▲(16.48%Upside)
Siegfried Holding AG's strong financial performance, underscored by a robust balance sheet and profitability, is the most significant factor driving the score. Technical analysis indicates mixed momentum, and while the stock appears somewhat overvalued, its attractive dividend yield provides a compensating factor.
Positive Factors
Financial Health
SFZN's balance sheet is seen as healthy, which supports potential US expansion and merger or acquisition activities.
Liquidity
A proposed 10:1 stock split could improve liquidity from retail and employee participation.
Market Position
SFZN is positioned to outperform peers due to its strong position in the generics market, especially against competitors facing higher tariffs.
Negative Factors
Future Projections
The margin guide leads to limited margin expansion potential for FY25, with scope for negative revisions in the near term.
Near-term Pressure
The company is expected to face near-term pressure with limited catalysts for stock improvement in the first half of the year.
Profit Margins
Analyst notes that generics are hit harder by tariffs compared to exclusive contracts, potentially impacting profit margins.

Siegfried Holding AG (SFZN) vs. iShares MSCI Switzerland ETF (EWL)

Siegfried Holding AG Business Overview & Revenue Model

Company DescriptionSiegfried Holding AG is a Swiss-based company operating in the pharmaceutical sector, primarily focused on the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company serves as a key partner for pharmaceutical and biotechnology companies worldwide, offering a broad range of integrated services from chemical development to the production of complex formulations.
How the Company Makes MoneySiegfried Holding AG generates revenue through its contract development and manufacturing organization (CDMO) services, which include the custom synthesis of active pharmaceutical ingredients (APIs) and the production of finished dosage forms (FDFs) for pharmaceutical companies. The company has established long-term partnerships with various global pharmaceutical and biotech firms, providing them with tailored solutions that range from early-stage development to commercial production. Siegfried's earnings are significantly driven by its ability to offer specialized expertise in chemical and pharmaceutical manufacturing processes, as well as its commitment to quality and compliance with regulatory standards. The company's diverse portfolio and global presence further enhance its revenue streams by allowing it to cater to a wide array of client needs in the healthcare industry.

Siegfried Holding AG Financial Statement Overview

Summary
Siegfried Holding AG demonstrates strong financial health with solid revenue growth and profitability. A robust balance sheet with no debt enhances financial stability. However, negative free cash flow indicates high capital expenditures, which could strain liquidity if not managed carefully.
Income Statement
85
Very Positive
Siegfried Holding AG has demonstrated consistent revenue growth, with a 1.81% increase from 2023 to 2024. The gross profit margin for 2024 was 25.42%, and the net profit margin was 12.37%, showing strong profitability. The EBIT margin improved to 15.39%, and the EBITDA margin stood at 22.36%, indicating efficient core operations and cost management.
Balance Sheet
92
Very Positive
The company has a robust balance sheet with zero debt in 2024, significantly improving its debt-to-equity position. Return on Equity (ROE) was strong at 16.33% for 2024, reflecting effective equity use. The equity ratio was 50.69%, suggesting a healthy capital structure with a significant portion of assets financed by equity.
Cash Flow
75
Positive
The operating cash flow to net income ratio was 1.05, indicating good cash generation relative to profit. However, the free cash flow was negative at -12.07 million, reflecting significant capital expenditures. The free cash flow to net income ratio was -0.08, showing a need for improved cash retention.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.29B1.27B1.23B1.10B845.06M
Gross Profit329.06M320.41M318.69M239.27M176.00M
EBITDA289.49M241.22M308.30M213.54M132.18M
Net Income160.06M112.77M156.49M95.60M60.87M
Balance Sheet
Total Assets1.93B1.86B1.79B1.67B1.24B
Cash, Cash Equivalents and Short-Term Investments39.61M56.63M91.62M72.97M54.44M
Total Debt490.10M525.00M590.00M560.00M377.50M
Total Liabilities953.81M1.02B1.08B1.06B746.62M
Stockholders Equity980.19M838.24M710.93M608.22M495.65M
Cash Flow
Free Cash Flow-12.07M71.51M19.30M-1.04M36.15M
Operating Cash Flow168.78M208.61M134.50M112.36M105.28M
Investing Cash Flow-190.35M-146.86M-103.72M-250.10M-69.02M
Financing Cash Flow3.04M-94.75M-10.68M156.24M-6.12M

Siegfried Holding AG Technical Analysis

Technical Analysis Sentiment
Negative
Last Price91.00
Price Trends
50DMA
94.77
Negative
100DMA
93.67
Negative
200DMA
100.43
Negative
Market Momentum
MACD
-1.42
Positive
RSI
43.23
Neutral
STOCH
30.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SFZN, the sentiment is Negative. The current price of 91 is below the 20-day moving average (MA) of 92.89, below the 50-day MA of 94.77, and below the 200-day MA of 100.43, indicating a bearish trend. The MACD of -1.42 indicates Positive momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 30.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SFZN.

Siegfried Holding AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
CHF4.35B36.208.87%1.20%4.84%7.45%
75
Outperform
CHF4.01B23.9618.36%4.52%1.82%39.11%
67
Neutral
CHF38.28B62.69
0.71%-2.13%2.50%
58
Neutral
CHF693.66M
3.15%62.88%
52
Neutral
$7.53B0.32-61.76%2.28%16.60%1.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:SFZN
Siegfried Holding AG
89.00
-8.98
-9.16%
CH:LONN
Lonza Group Ltd
558.00
56.91
11.36%
CH:BANB
Bachem Holding AG
57.00
-26.84
-32.01%
CH:PPGN
PolyPeptide Group AG
20.30
-9.60
-32.11%

Siegfried Holding AG Corporate Events

Siegfried Holding AG Shareholders Approve Key Proposals at AGM 2025
Apr 10, 2025

At its 122nd Annual General Meeting, Siegfried Holding AG’s shareholders approved all proposals made by the Board of Directors, including a capital reduction through a nominal value repayment of CHF 3.80 per share and a 1:10 share split to enhance market liquidity. The meeting also addressed Siegfried’s exposure to US tariffs, noting that a small portion of its revenue is subject to potential tariffs, with most imports either exempt or picked up directly by customers. These decisions are expected to impact shareholder returns positively and improve share liquidity, while the company’s limited exposure to US tariffs suggests minimal impact on its operations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 14, 2025